【结 构 式】 |
【药物名称】Nilutamide, RU-23908, Nilandron, Anandron 【化学名称】5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione 【CA登记号】63612-50-0 【 分 子 式 】C12H10F3N3O4 【 分 子 量 】317.2264 |
【开发单位】Aventis Pharma (Originator) 【药理作用】Oncolytic Drugs, Prostate Cancer Therapy, Antiandrogens |
合成路线1
3-Trifluoromethyl-4-nitrophenylisocyanate (I) and 2-amino-2-cyanopropane (II) are condensed. After concentration by distillation under reduced pressure and chromatography of the residue on silica gel (elution with dichloromethane: acetone, 8:2 v/v), the intermediate 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-5-imino-2-imidazolidinone) (III) is obtained. This intermediate, in suspension in aqueous hydrochloric acid, is heated, then cooled and poured into water. The precipitate, filtered, washed and dried, is anandron (RU-23908), which can be recrystallized in an ethanolic medium.
【1】 Perronet, J.; Girault, P.; Bonne, C. (Aventis Pharma SA); 1-(3-(4-O-Trifluoromethyl-4-(4-O-nitrophenyl)-4,4-dimethyl)imidazolidines. DE 2649925; ES 452746; FR 2329276; FR 7533084; GB 1518444; JP 52057176; US 4097578 . |
【2】 Ojasoo, T.; Nilutamide. Drugs Fut 1987, 12, 8, 763. |